title: [Involvement of miR-200a in chemosensitivity regulation of ovarian cancer].
abstract: OBJECTIVE
  To explore the role of miR-200a in chemosensitivity regulation of ovarian cancer.
  
  
  METHODS
  Firstly miR-200a was up-regulated in ovarian cancer cell lines (SKOV-3 and ES-2) by lentiviral vector. Then the effects of miR-200a on cytotoxicity of paclitaxel and cisplatin were investigated by methyl thiazolyl tetrazolium (MTT). Furthermore miR-200a regulation of chemoresistance associated with ATP-binding cassette (ABC) family genes expression was detected by quantitative real-time polymerase chain reaction (PCR) and Western blot. Finally the interaction between miR-200a and ABCG2 mRNA 3'untranslated region (3'-UTR) was verified by dual-luciferase reporter assay.
  
  
  RESULTS
  An over-expression of miR-200a were successfully achieved in SKOV-3 and ES-2 cells. MiR-200a enhanced the chemosensitivity of SKOV-3 and ES-2 to paclitaxel, but not to cisplatin. Chemoresistance associated ABC family (ABCB3, ABCC1, ABCC2, ABCC3, ABCG2) were down-regulated by miR-200a at several levels. However, the direct interaction between miR-200a and the 3'-UTR of ABCG2 mRNA was not found.
  
  
  CONCLUSIONS
  An over-expression of miR-200a may increase chemosensitivity to paclitaxel in ovarian cancer cells through negatively regulated chemoresistance associated ABC family. However, no direct action on 3'-UTR of ABCG2 was not found after its down-regulation by miR-200a.
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Na
authors.initials: N
authors.lastname: Liu
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zeng
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Xiaomei
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Yang
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Di
authors.initials: D
authors.lastname: Liao
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Gaowen
authors.initials: G
authors.lastname: Chen
authors.affiliation: Department of Obstetrics & Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China. Email: wyf2015@163.com.
authors.forename: Yifeng
authors.initials: Y
authors.lastname: Wang
mesh_terms: D020413:3' Untranslated Regions; D045744:Cell Line, Tumor; D002945:Cisplatin; D015536:Down-Regulation; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D000089762:Multidrug Resistance-Associated Protein 2; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel; D012333:RNA, Messenger; D015398:Signal Transduction; D015854:Up-Regulation
chemical_list: D020413:3' Untranslated Regions; C000715087:ABCC2 protein, human; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D000089762:Multidrug Resistance-Associated Protein 2; D012333:RNA, Messenger; D017239:Paclitaxel; D002945:Cisplatin